Normobaric Hypoxic Training and Multiple Sclerosis
Cardiorespiratory, Metabolic and Immunoregulatory Response to Hypoxia in Multiple Sclerosis Patients: A Pilot Study
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Hypoxic training
Placebo
- Normoxic training
What it measured
Main measures
Activity energy expenditure measured by indirect calorimetry (respiratory chamber)
Change from baseline at 4 weeks
Who could take part
MS (type not specified) · 20 to 60
Show the full criteria
Inclusion criteria
* stable immunomodulatory therapy * expanded disability status scale score \< 4.5 * body mass index 18.5 - 29.9 kg/m2
Exclusion criteria
* clinically relevant heart, lung, liver, and kidney diseases
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To study the effects of normobaric hypoxic training on cardiorespiratory fitness, resting, postprandial and exercise activity energy expenditure, immunoregulatory functions and serum erythropoietin levels in relapsing-remitting multiple sclerosis patients.
Papers
Loading reviews and guidelines…
History
Started
Jul 2015
Main results due
Dec 2017
Finished
Jul 2018